AMLN Amylin Pharmaceuticals, Inc. (MM)

Amylin Pharmaceuticals Files Shelf Registration Statement SAN DIEGO, Dec. 11 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. today announced that it has filed a shelf registration statement with the Securities and Exchange Commission (SEC). Upon being declared effective by the SEC, the shelf registration statement will allow the Company to sell up to $300 million of various securities in one or more offerings in the future. The terms of any offering will be established at the time of sale. The shelf registration statement relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the shelf registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities, in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities law of any such state. A written prospectus, when available, meeting the requirements of Section 10 of the Securities Act of 1933, as amended, may be obtained from the Company at 9360 Towne Centre Drive, San Diego, CA 92121, Attention: Investor Relations. Amylin Pharmaceuticals is committed to improving the lives of people with diabetes and other metabolic diseases through the discovery, development and commercialization of innovative, cost-effective medicines. This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In particular, due to market conditions or otherwise, Amylin Pharmaceuticals, Inc. may be unable to complete any sale of securities under the shelf registration statement. DATASOURCE: Amylin Pharmaceuticals, Inc. CONTACT: Mark G. Foletta, Vice President of Finance and Chief Financial Officer of Amylin Pharmaceuticals, Inc., +1-858-552-2200 Web site: http://www.amylin.com/

Copyright